Multiepitope Peptide Vaccination in Melanoma
Phase 2
- Conditions
- Metastatic Melanoma
- Registration Number
- NCT00153569
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- Metastatic melanoma
- HLA-A1, -A2, -A24, -B44
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Clinical efficacy
- Secondary Outcome Measures
Name Time Method Immune response Safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie multiepitope peptide vaccine efficacy in metastatic melanoma?
How does multiepitope peptide vaccination compare to checkpoint inhibitors in stage IV melanoma treatment?
Which biomarkers correlate with response to multiepitope vaccines with GM-CSF and KLH adjuvants in melanoma?
What are the safety profiles of GM-CSF and KLH adjuvants in combination with peptide vaccines for cancer?
What are the current developments in peptide-based immunotherapies for metastatic melanoma post-2005?
Trial Locations
- Locations (1)
Hem&Onc Charité CBF
🇩🇪Berlin, Germany
Hem&Onc Charité CBF🇩🇪Berlin, Germany